The new trials include the following disease indications: follicular non-Hodgkin’s lymphoma, metastatic breast cancer, metastatic sarcoma, chronic myelogenous leukemia, and non-small cell lung cancer.
The new oncology clinical trials are targeted to achieve enrollment of over 500 cancer patients with the participation of approximately 165 Pharmatech research network sites.
Pharmatech will manage the trials using its innovative just-in-time approach. This streamlined approach was created to increase enrollment in oncology clinical trials. This patient first initiative allows for identification of cancer patients through basic standard of care procedures, so the site opens only if the patient qualifies for the study.
Patient enrollment is also expected to increase because a protocol is rolled out to a large number of qualified research network sites with minimal expense of time and capital for both the sites and sponsors.